OPEN Cancer research and treatment : official journal of Korean Cancer Association | 14 Nov 2017
J Lee, YJ Shin, K Lee, HJ Cho, JK Sa, SY Lee, SH Kim, J Lee, Y Yoon and DH Nam
Glioblastoma (GBM) is classified as one of the most aggressive and lethal brain tumor. Great strides have been made in understanding the genomic and molecular underpinnings of GBM, which translated into development of new therapeutic approaches to combat such deadly disease. However, there are only few therapeutic agents that can effectively inhibit GBM invasion in a clinical framework. In an effort to address such challenges, we have generated anti-SEMA3A monoclonal antibody as a potential therapeutic antibody against GBM progression.
* Data courtesy of Altmetric.com